<DOC>
	<DOC>NCT00276380</DOC>
	<brief_summary>The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.</brief_summary>
	<brief_title>A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Neurologic Manifestations</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Patient having had a single infarct in the carotid artery territory 3 to 8 days before inclusion Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5) Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time) test in the normal values of the laboratory Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8 days prior Patient with known preexistent cerebral infarction Infarct damaged area bigger than 1/3 hemisphere Patient having a score below the cutoff point at Frenchay Aphasia Short Test</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>